Impact of common risk factors of fibrosis progression in chronic hepatitis C

Gut

Volumn 64, Issue 10, 2015, Pages 1605-1615

  Rueger S ^a,b,c   Bochud, P Y ^d   Dufour, J F ^e   Mullhaupt B ^f   Semela, D ^g   Heim, M H ^h   Moradpour, D ^d   Cerny, A ⁱ   Malinverni, R ^j   Booth, D R ^k   Suppiah, V ^k   George, J ^k   Argiro, L ^l   Halfon, P ^m   Bourliere M ⁿ   Talal, A H ^o   Jacobson, I M ^o   Patin, E ^p,q   Nalpas, B ^q,r   Poynard, T ^s   Pol, S ^q,r   Abel, L ^p,q,t   Kutalik, Z ^b,c   Negro, F ^u   more..

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ Clinica Luganese Moncucco   (Switzerland)

^j Department of Internal Medicine and Infectious Diseases   (Switzerland)

^k UNIVERSITY OF SYDNEY   (Australia)

^l Aix Marseille university   (France)

^m Hospital Ambroise Pare   (France)

ⁿ HÔPITAL SAINT JOSEPH   (France)

^o WEILL CORNELL MEDICAL COLLEGE   (United States)

^p IMAGINE INSTITUTE   (France)

^q UNIVERSITÉ PARIS DESCARTES   (France)

^r Hôpital Pitié Salpêtrière ^*  (France)

^s SORBONNE UNIVERSITÉ   (France)

^t ROCKEFELLER UNIVERSITY   (United States)

^u GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; BODY MASS; CHRONIC HEPATITIS C; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; DRINKING BEHAVIOR; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MERTK GENE; MIXED INFECTION; PNPLA3 GENE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TULP1 GENE; VIRUS GENE; BIOPSY; COMPLICATION; GENETICS; HEPACIVIRUS; INCIDENCE; LIVER CIRRHOSIS; PROCEDURES; RETROSPECTIVE STUDY; RISK ASSESSMENT; SWITZERLAND; TIME; VIROLOGY;

VIRUS RNA;

BIOPSY; DISEASE PROGRESSION; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; RNA, VIRAL; SWITZERLAND; TIME FACTORS;

EID: 84941360952     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-306997     Document Type: Article

References (45)

1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013;10:553-62.
2. Bochud PY, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009;51:655-66.
3. Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Liver Int 2009;29(SUPPL. 1):15-8.
4. Probst A, Dang T, Bochud M, et al. Role of viral genotypes in fibrosis progression in chronic hepatitis C: a systematic review and meta-analysis. J Viral Hepat 2011;18:745-59.
5. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
6. Mallat A, Hezode C, Lotersztajn S. Environmental factors as disease accelerators during chronic hepatitis C. J Hepatol 2008;48:657-65.
7. Halangk J, Sarrazin C, Neumann K, et al. Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection. J Hepatol 2008;49:339-45.
8. Sermasathanasawadi R, Kato N, Muroyama R, et al. Association of interferon regulatory factor-7 gene polymorphism with liver cirrhosis in chronic hepatitis C patients. Liver Int 2008;28:798-806.
9. Marcolongo M, Young B, Dal Pero F, et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 2009;50:1038-44.
10. Nalpas B, Lavialle-Meziani R, Plancoulaine S, et al. Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection. Gut 2010;59:1120-6.
11. Iwata R, Baur K, Stieger B, et al. A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. Clin Sci (Lond) 2011;120:287-96.
12. Bochud PY, Bibert S, Kutalik Z, et al. IL28B alleles associated with poor HCV clearance are protective against liver necroinflammatory activity and fibrosis progression in patients infected with non-1 HCV genotypes. Hepatology 2012;55:384-94.
13. Patin E, Kutalik Z, Guergnon J, et al. Genome-wide association study of liver fibrosis progression in HCV-infected patients. Gastroenterology 2012;143:1244-52.e12.
14. Urabe Y, Ochi H, Kato N, et al. A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region. J Hepatol 2013;58:875-82.
15. Prasad L, Masserey V, Zwahlen M, et al. Cohort Profile: The Swiss Hepatitis C Cohort Study. Int J Epidemiol 2007;36:731-7.
16. Leandro G, Mangia A, Hui J, et al. The relationship between hepatic steatosis, inflammation and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;130:1636-42.
17. Lange CM, Kutalik Z, Morikawa K, et al. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology 2012;55:1038-47.
18. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-45, 1345 e1331-1337.
19. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2009.
20. Rückinger S, von Kries R, Toschke AM. An illustration of and programs estimating attributable fractions in large scale surveys considering multiple risk factors. BMC Med Res Methodol 2009;9:7.
21. Greenland S, Drescher K. Maximum likelihood estimation of the attributable fraction from logistic models. Biometrics 1993;49:865-72.
22. Canty A, Ripley B. Boot: Bootstrap R (S-Plus) Functions. R package version 1.3-9, 2013.
23. Davison AC, Hinkley DV. Bootstrap methods and their applications. Cambridge: Cambridge University Press, 1997.
24. Lee SH, Goddard ME, Wray NR, et al. A better coefficient of determination for genetic profile analysis. Genet Epidemiol 2012;36:214-24.
25. Steyerberg EW Clinical prediction models a practical approach to development, validation, and updating. New York: Springer, 2009.
26. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4.
27. Han B, Eskin E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. Am J Hum Gen 2011;88:586-98.
28. Xiao R, Boehnke M. Quantifying and correcting for the winner's curse in genetic association studies. Genet Epidemiol 2009;33:453-62.
29. Pessione F, Ramond MJ, Njapoum C, et al. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 2001;34:121-5.
30. Hézode C, Lonjon I, Roudot-Thoraval F, et al. Impact of smoking on histological liver lesions in chronic hepatitis C. Gut 2003;52:126-9.
31. Hézode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005;42:63-71.
32. Monto A, Alonzo J, Watson JJ, et al. Steatosis in chronic hepatitis C: relative contribution of obesity, diabetes mellitus, and alcohol. Hepatology 2002;36:729-36.
33. Innes HA, Hutchinson SJ, Barclay S, et al. Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness. Hepatology 2013;57:451-60.
34. Poynard T, Lebray P, Ingiliz P, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010;10:40.
35. Prasad L, Spicher VM, Negro F, et al. Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study. J Viral Hepat 2009;16:644-9.
36. Jin M, Cai S, Guo J, et al. Alcohol drinking and all cancer mortality: a meta-analysis. Ann Oncol 2013;24:807-16.
37. Goossens N, Negro F. Is the genotype 3 of the hepatitis C virus the new villain? Hepatology 2014;59:2403-12.
38. Scott RS, McMahon EJ, Pop SM, et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 2001;411:207-11.
39. + T cell responses to apoptotic self-antigens correlate with the chronic evolution of hepatitis C virus infection. PLoS Pathog 2012;8:e1002759.
40. Hagan H, Thiede H, Des Jarlais DC Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. Epidemiology 2004;15:543-9.
41. Greenland S, Robins JM. Conceptual problems in the definition and interpretation of attributable fractions. Am J Hygiene 1998;128:1185-97.
42. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am J Public Health 1998;88:15-19.
43. Pearl J. Understanding propensity scores. In: Pearl J, ed. Causality: models, reasoning, and inference. 2nd edn. New York: Cambridge University Press, 2009.
44. Sjölander A. A cautionary note on the use of attributable fractions in cohort studies. Stat Methods Med Res 2014. Published Online First: 24 Feb 2014.
45. Delgado-Rodríguez M, Llorca J. Bias. J Epidemiol Community Health 2004;58:635-41.